Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2016 · 10-K
Revenue$9.08M$9.08M+13.0% vs Q4 2015 Net Income-$749.69K-$749.69KN/M vs Q4 2015 EPS Diluted-$0.05-$0.05N/M vs Q4 2015 Operating Income-$957,371N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$787,197−38.4% Margins · derivedOperating margin-10.5%−12.6 pt vs Q4 2015
Net margin-8.3%−10.1 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 13, 2017 · 72 d after period end